FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a fusion protein – an IL-1 antagonist. Said protein contains a functional domain of human IL-1RA, represented by an amino acid sequence corresponding to positions 26-177 of sequence SEQ ID NO: 1, Fc fragment of human IgG4 with sequence SEQ ID NO: 3 and linker sequence RS. Present invention also relates to a nucleic acid molecule coding said fused protein, an expression vector and a cell transfected with said vector.
EFFECT: invention provides potentially high degree of safety of therapeutic application of protein in combination with improved pharmacokinetic properties.
9 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
| NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
| NUCLEOTIDE SEQUENCE, WHICH CODES A FUSION PROTEIN CONSISTING OF A SOLUBLE EXTRACELLULAR DOMAIN OF HUMAN TNFR1 AND A CONSTANT PORTION OF A HEAVY CHAIN OF HUMAN IgG4 | 2018 |
|
RU2689522C1 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| MODIFIED INTERLEUKIN-7 PROTEIN AND METHODS FOR USE THEREOF | 2016 |
|
RU2708160C2 |
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
